| Literature DB >> 33335236 |
Akiomi Yoshihisa1, Koichiro Watanabe2, Yu Sato2, Shinji Ishibashi3, Mitsuko Matsuda3, Yukio Yamadera3, Yasuhiro Ichijo2, Tetsuro Yokokawa2, Tomofumi Misaka2, Masayoshi Oikawa2, Atsushi Kobayashi2, Yasuchika Takeishi2.
Abstract
We aimed to clarify clinical implications of intrarenal hemodynamics assessed by intrarenal Doppler ultrasonography (IRD) and their prognostic impacts in heart failure (HF). We performed a prospective observational study, and examined IRD and measured interlobar renal artery velocity time integral (VTI) and intrarenal venous flow (IRVF) patterns (monophasic or non-monophasic pattern) to assess intrarenal hypoperfusion and congestion in HF patients (n = 341). Seven patients were excluded in VTI analysis due to unclear imaging. The patients were divided into groups based on (A) VTI: high VTI (VTI ≥ 14.0 cm, n = 231) or low VTI (VTI < 14.0 cm, n = 103); and (B) IRVF patterns: monophasic (n = 36) or non-monophasic (n = 305). We compared post-discharge cardiac event rate between the groups, and right-heart catheterization was performed in 166 patients. Cardiac index was lower in low VTI than in high VTI (P = 0.04), and right atrial pressure was higher in monophasic than in non-monophasic (P = 0.03). In the Kaplan-Meier analysis, cardiac event rate was higher in low VTI and monophasic groups (P < 0.01, respectively). In the Cox proportional hazard analysis, the combination of low VTI and a monophasic IRVF pattern was a predictor of cardiac events (P < 0.01). IRD imaging might be associated with cardiac output and right atrial pressure, and prognosis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33335236 PMCID: PMC7746684 DOI: 10.1038/s41598-020-79351-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comparisons of patient characteristics between interlobular renal artery VTI groups.
| High VTI ( | Low VTI ( | ||||
|---|---|---|---|---|---|
| Age (years) | 65.2 ± 13.0 | 69.6 ± 12.3 | < 0.01 | − 0.13 | 0.02 |
| Male sex (n, %) | 139 (60.2) | 68 (66.0) | 0.33 | − 0.06 | 0.28 |
| Body mass index (kg/m2) | 24.0 ± 4.3 | 23.3 ± 5.3 | 0.25 | 0.07 | 0.18 |
| Systolic blood pressure (mmHg) | 120.1 ± 17.1 | 115.6 ± 17.8 | 0.03 | 0.11 | 0.05 |
| Diastolic blood pressure (mmHg) | 69.5 ± 12.4 | 68.4 ± 12.9 | 0.47 | − 0.04 | 0.43 |
| Heart rate (bpm) | 68.5 ± 12.9 | 75.5 ± 15.0 | < 0.01 | − 0.38 | < 0.01 |
| NYHA class III or IV (n, %) | 11 (4.8) | 11 (10.7) | 0.06 | − 0.12 | 0.03 |
| Atrial fibrillation (n, %) | 71 (30.7) | 49 (47.6) | < 0.01 | − 0.07 | < 0.01 |
| Hypertension (n, %) | 134 (58.0) | 71 (68.6) | 0.07 | − 0.05 | < 0.01 |
| Dyslipidemia (n, %) | 163 (70.6) | 75 (72.8) | 0.70 | 0.04 | 0.42 |
| Diabetes mellitus (n, %) | 74 (32.0) | 37 (35.9) | 0.53 | − 0.02 | 0.74 |
| Chronic kidney disease (n, %) | 99 (42.9) | 74 (71.8) | < 0.01 | − 0.30 | < 0.01 |
| Anemia (n, %) | 88 (38.1) | 57 (55.3) | < 0.01 | − 0.08 | < 0.01 |
| Hemoglobin (g/dL) | 13.5 ± 1.9 | 12.9 ± 2.2 | 0.02 | 0.13 | 0.02 |
| B-type natriuretic peptide (pg/ml) | 57.7 (19.2–166.7) | 257.6 (98.9–526.4) | < 0.01 | − 0.28 | < 0.01 |
| Creatinine (mg/dL) | 0.92 ± 0.37 | 1.26 ± 0.94 | < 0.01 | − 0.22 | < 0.01 |
| eGFR (mL/min/1.73 cm2) | 62.4 ± 17.2 | 49.1 ± 16.5 | < 0.01 | 0.31 | < 0.01 |
| Sodium (mEq/L) | 139.7 ± 2.7 | 139.2 ± 3.5 | 0.14 | 0.10 | 0.06 |
| Urinary protein creatinine ratio (g/g *Creatinine) | 0 (0–0.06) | 0 (0–0.25) | 0.07 | − 0.14 | 0.01 |
| Urinary albumin creatinine ratio (mg/g *Creatinine) | 11.5 (5.0–35.8) | 25.0 (9–125.5) | 0.04 | − 0.21 | < 0.01 |
| Urinary β2 micro globulin (µg/mL) | 0.11 (0.06–0.20) | 0.12 (0.05–0.40) | 0.99 | − 0.08 | 0.18 |
| Urinary NAG (U/L) | 4.5 (2.4–8.7) | 6.6 (3.1–14.6) | 0.02 | − 0.16 | < 0.01 |
| LVEF (%) | 56.1 ± 15.4 | 49.3 ± 16.5 | < 0.01 | 0.23 | < 0.01 |
| Left atrial volume index (mL/m2) | 48.0 ± 27.7 | 64.4 ± 35.2 | < 0.01 | − 0.20 | < 0.01 |
| LVOT-VTI (cm) | 18.2 ± 4.8 | 15.6 ± 5.3 | < 0.01 | 0.28 | < 0.01 |
| Mitral valve E/e′ | 12.4 ± 8.0 | 15.7 ± 8.8 | < 0.01 | − 0.22 | < 0.01 |
| RA end systolic area (cm2) | 17.2 ± 6.3 | 21.0 ± 7.2 | < 0.01 | − 0.25 | < 0.01 |
| RV area diastole (cm2) | 19.6 ± 7.0 | 23.2 ± 9.3 | 0.04 | − 0.26 | < 0.01 |
| RV area systole (cm2) | 12.0 ± 5.5 | 16.4 ± 8.7 | < 0.01 | − 0.30 | < 0.01 |
| RV fractional area change (%) | 40.0 ± 10.9 | 32.8 ± 12.5 | < 0.01 | 0.32 | < 0.01 |
| Inferior vena cava diameter (mm) | 15.1 ± 4.0 | 16.2 ± 4.8 | 0.07 | − 0.07 | 0.22 |
| TRPG (mmHg) | 24.8 ± 12.7 | 29.5 ± 16.5 | 0.02 | − 0.23 | < 0.01 |
| n = 110 | n = 56 | ||||
| PAP mean (mmHg) | 23.8 ± 9.8 | 29.5 ± 12.3 | < 0.01 | − 0.26 | < 0.01 |
| PAP systolic (mmHg) | 35.5 ± 14.9 | 42.6 ± 20.5 | < 0.01 | − 0.24 | < 0.01 |
| PAP diastolic (mmHg) | 14.9 ± 7.2 | 19.9 ± 8.6 | < 0.01 | − 0.29 | < 0.01 |
| Right atrial pressure mean (mmHg) | 6.7 ± 3.7 | 8.5 ± 3.6 | < 0.01 | − 0.17 | 0.03 |
| PAWP mean (mmHg) | 13.5 ± 6.4 | 17.7 ± 8.8 | < 0.01 | − 0.18 | 0.02 |
| Cardiac output (L/min) | 4.22 ± 1.19 | 3.98 ± 1.02 | 0.16 | 0.13 | 0.09 |
| Cardiac index (L/min/m2) | 2.65 ± 0.64 | 2.36 ± 0.69 | 0.04 | 0.27 | < 0.01 |
| RAS inhibitors (n, %) | 180 (77.9) | 77 (74.8) | 0.57 | − 0.18 | 0.53 |
| β-Blockers (n, %) | 128 (55.4) | 76 (73.8) | < 0.01 | 0.31 | < 0.01 |
| Diuretics (n, %) | 94 (40.7) | 77 (74.8) | < 0.01 | 0.32 | < 0.01 |
| Inotropic agents (n, %) | 14 (6.1) | 16 (15.5) | < 0.01 | 0.28 | < 0.01 |
VTI velocity time integral, NYHA New York Heart Association, eGFR estimated glomerular filtration rate, NAG N-acetyl-β-d-glucosaminidase, LVEF left ventricular (LV) ejection fraction, LVOT LV outflow tract, RA right atrial, RV right ventriclar, TRPG tricuspid regurgitation pressure gradient, PAP pulmonary artery pressure, PAWP pulmonary artery wedge pressure, RAS renin-angiotensin system.
Comparisons of patient characteristics among IRVF patterns.
| Non-monophasic ( | Monophasic ( | ||||
|---|---|---|---|---|---|
| Age (years) | 65.9 ± 12.9 | 72.0 ± 11.8 | < 0.01 | 0.05 | < 0.01 |
| Male sex (n, %) | 196 (64.3) | 17 (47.2) | 0.07 | − 0.70 | 0.06 |
| Body mass index (kg/m2) | 23.9 ± 4.7 | 22.4 ± 3.6 | 0.05 | − 0.09 | 0.05 |
| Systolic blood pressure (mmHg) | 119.0 ± 17.2 | 117.1 ± 19.3 | 0.55 | − 0.01 | 0.54 |
| Diastolic blood pressure (mmHg) | 69.6 ± 12.3 | 66.7 ± 14.2 | 0.20 | − 0.02 | 0.19 |
| Heart rate (bpm) | 71.0 ± 13.8 | 67.8 ± 14.7 | 0.20 | − 0.02 | 0.19 |
| NYHA class III or IV (n, %) | 21 (6.9) | 2 (5.6) | 1.00 | − 0.23 | 0.76 |
| Atrial fibrillation (n, %) | 104 (34.1) | 21 (58.3) | < 0.01 | 0.99 | < 0.01 |
| Hypertension (n, %) | 183 (60.0) | 24 (66.7) | 0.48 | 0.29 | 0.44 |
| Dyslipidemia (n, %) | 217 (71.1) | 23 (63.9) | 0.44 | − 0.33 | 0.37 |
| Diabetes mellitus (n, %) | 101 (33.1) | 11 (30.6) | 0.85 | − 0.19 | 0.76 |
| Chronic kidney disease (n, %) | 154 (50.5) | 24 (66.7) | 0.08 | 0.67 | 0.07 |
| Anemia (n, %) | 130 (42.6) | 20 (55.6) | 0.16 | 0.52 | 0.14 |
| Hemoglobin (g/dL) | 13.4 ± 2.0 | 12.7 ± 2.1 | 0.06 | − 0.17 | 0.06 |
| B-type natriuretic peptide (pg/ml) | 86.4 (23.5–251.8) | 218.9 (142.9–547.9) | < 0.01 | 0.01 | 0.01 |
| Creatinine (mg/dL) | 1.06 ± 0.78 | 1.04 ± 0.39 | 0.87 | − 0.04 | 0.87 |
| eGFR (mL/min/1.73 cm2) | 58.8 ± 19.3 | 52.1 ± 15.0 | 0.04 | − 0.02 | 0.04 |
| Sodium (mEq/L) | 139.5 ± 2.9 | 139.9 ± 3.6 | 0.50 | 0.04 | 0.50 |
| Urinary protein creatinine ratio (g/g *Creatinine) | 0 (0–0.09) | 0 (0–0.203) | 0.54 | − 0.17 | 0.69 |
| Urinary albumin creatinine ratio (mg/g *Creatinine) | 14.5 (6–42.8) | 18.5 (8–87.5) | 0.67 | 0.01 | 0.75 |
| Urinary β2 micro globulin (µg/mL) | 011 (0.05–0.24) | 0.12 (0.05–0.28) | 0.49 | − 0.02 | 0.69 |
| Urinary NAG (U/L) | 4.8 (2.4–9.7) | 6.2 (3.8–15.0) | 0.35 | 0.01 | 0.29 |
| LVEF (%) | 54.5 ± 15.3 | 49.2 ± 19.5 | 0.06 | − 0.02 | 0.06 |
| Left atrial volume index (mL/m2) | 51.0 ± 29.4 | 74.7 ± 38.0 | < 0.01 | 0.02 | < 0.01 |
| LVOT-VTI (cm) | 17.3 ± 5.0 | 17.3 ± 6.0 | 0.99 | 0.01 | 0.99 |
| Mitral valve E/e′ | 12.8 ± 7.8 | 18.8 ± 10.9 | < 0.01 | 0.06 | < 0.01 |
| RA end-systolic area (cm2) | 17.8 ± 6.7 | 23.1 ± 7.3 | < 0.01 | 0.10 | < 0.01 |
| RV area diastole (cm2) | 20.6 ± 7.7 | 20.9 ± 8.8 | 0.88 | 0.01 | 0.87 |
| RV area systole (cm2) | 13.1 ± 6.6 | 14.0 ± 8.4 | 0.63 | 0.02 | 0.63 |
| RV fractional area change (%) | 38.0 ± 11.5 | 35.1 ± 13.9 | 0.34 | − 0.02 | 0.34 |
| Inferior vena cava diameter (mm) | 15.3 ± 4.3 | 17.0 ± 4.2 | 0.03 | 0.09 | 0.03 |
| TRPG (mmHg) | 25.4 ± 12.6 | 34.3 ± 21.6 | < 0.01 | 0.03 | < 0.01 |
| n = 139 | n = 27 | ||||
| PAP mean (mmHg) | 25.3 ± 10.9 | 29.2 ± 11.6 | 0.11 | 0.03 | 0.10 |
| PAP systolic (mmHg) | 37.4 ± 16.6 | 41.8 ± 20.8 | 0.23 | 0.01 | 0.24 |
| PAP diastolic (mmHg) | 16.3 ± 8.0 | 19.0 ± 8.0 | 0.31 | 0.04 | 0.12 |
| Right atrial pressure mean (mmHg) | 7.2 ± 3.9 | 9.0 ± 2.7 | 0.03 | 0.10 | 0.02 |
| PAWP mean (mmHg) | 14.7 ± 7.7 | 16.6 ± 6.0 | 0.21 | 0.03 | 0.21 |
| Cardiac output (L/min) | 4.19 ± 1.20 | 4.07 ± 1.15 | 0.65 | − 0.08 | 0.65 |
| Cardiac index (L/min/m2) | 2.59 ± 0.68 | 2.66 ± 0.59 | 0.60 | 0.16 | 0.59 |
| RAS inhibitors (n, %) | 234 (76.7) | 30 (83.3) | 0.53 | 0.42 | 0.37 |
| β-Blockers (n, %) | 183 (60.0) | 25 (69.4) | 0.37 | 0.42 | 0.27 |
| Diuretics (n, %) | 147 (48.2) | 28 (77.8) | < 0.01 | 0.87 | < 0.01 |
| Inotropic agents (n, %) | 29 (9.5) | 1 (2.8) | 0.34 | 0.27 | 0.21 |
IRVF intrarenal venous flow, NYHA New York Heart Association, Egfr estimated glomerular filtration rate, NAG N-acetyl-β-d-glucosaminidase, LVEF left ventricular (LV) ejection fraction, LVOT LV outflow tract, VTI velocity time integral, RA right atrial, RV right ventricular, TRPG tricuspid regurgitation pressure gradient, PAP pulmonary artery pressure, PAWP pulmonary artery wedge pressure, RAS renin-angiotensin system.
Figure 1Kaplan–Meier analysis for cardiac events. VTI velocity time integral, IRVF intrarenal venous flow.
Figure 2Cardiac events stratified by combination of VTI and IRVF pattern. VTI velocity time integral, IRVF intrarenal venous flow.
Cox proportional hazard model of cardiac events (factors in parameters of renal ultrasonography).
| Cardiac event (42 events/334 patients) | HR | 95% CI | P value |
|---|---|---|---|
| VTI (low vs. high) | 3.65 | 1.97–6.75 | < 0.01 |
| VTI (low vs. high)* | 3.06 | 1.62–5.78 | < 0.01 |
| IRVF pattern (monophasic vs. non-monophasic) | 2.86 | 1.46–5.59 | < 0.01 |
| IRVF pattern (monophasic vs. non-monophasic)* | 2.25 | 1.11–4.55 | 0.02 |
| Subset 1 (high VTI and non-monophasic IRVF) | Reference | – | – |
| Subset 2 (high VTI and monophasic IRVF) | 2.92 | 1.06–8.07 | 0.04 |
| Subset 2 (high VTI and monophasic IRVF)* | 2.09 | 0.74–5.93 | 0.16 |
| Subset 3 (low VTI and non-monophasic IRVF) | 3.57 | 1.73–7.38 | < 0.01 |
| Subset 3 (low VTI and non-monophasic IRVF)* | 2.92 | 1.39–6.14 | < 0.01 |
| Subset 4 (low VTI and monophasic IRVF) | 8.36 | 3.37–20.75 | < 0.01 |
| Subset 4 (low VTI and monophasic IRVF)* | 6.47 | 2.50–16.77 | < 0.01 |
HR hazard ratio, CI confidence interval, VTI velocity time integral, IRVF intrarenal venous flow.
*Adjusted: adjusted for age and sex.
Figure 3Abdominal ultrasonography.